Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.

× No keyword cloud information.

9 in total

1. Comment on: "Regorafenib: Start Low and Go Slow".

Authors: Christelle de la Fouchardière
Journal: Target Oncol Date: 2016-02 Impact factor: 4.493

2. Author's Reply to Christelle de la Fouchardière: "Regorafenib: Start Low and Go Slow".

Authors: Samer Tabchi; Marwan Ghosn
Journal: Target Oncol Date: 2016-02 Impact factor: 4.493

3. Optimizing Regorafenib Dosing and Patient Management in Colorectal Cancer in Latin America: Perspectives from Argentina.

Authors: Mariano Dioca; Juan Manuel O'Connor
Journal: Oncologist Date: 2021-03-06

4. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.

Authors: Eric Van Cutsem; Erika Martinelli; Stefano Cascinu; Alberto Sobrero; Maria Banzi; Jean-François Seitz; Carlo Barone; Marc Ychou; Marc Peeters; Baruch Brenner; Ralf Dieter Hofheinz; Evaristo Maiello; Thierry André; Andrea Spallanzani; Rocio Garcia-Carbonero; Yull E Arriaga; Udit Verma; Axel Grothey; Christian Kappeler; Ashok Miriyala; Joachim Kalmus; Alfredo Falcone; Alberto Zaniboni
Journal: Oncologist Date: 2018-09-06

5. Treatment of metastatic refractory colorectal cancer following regorafenib failure.

Authors: Nobumichi Takeuchi; Kumiko Koike; Sonomi Yoshida; Akiko Kudo; Nodoka Sekiguchi; Ataru Nakayama; Kouji Kubota; Takashi Rokuhara; Masayuki Kitahara
Journal: Mol Clin Oncol Date: 2017-06-29

6. Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study.

Authors: Chun-Yu Lin; Tseng-Hsi Lin; Chou-Chen Chen; Ming-Cheng Chen; Chou-Pin Chen
Journal: PLoS One Date: 2018-01-05 Impact factor: 3.240

7. Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial.

Authors: Allen Lee Cohn; Takayuki Yoshino; Volker Heinemann; Radka Obermannova; György Bodoky; Jana Prausová; Rocio Garcia-Carbonero; Tudor Ciuleanu; Pilar Garcia-Alfonso; David C Portnoy; Eric Van Cutsem; Kentaro Yamazaki; Philip R Clingan; Jonathon Polikoff; Sara Lonardi; Lisa M O'Brien; Ling Gao; Ling Yang; David Ferry; Federico Nasroulah; Josep Tabernero
Journal: Cancer Chemother Pharmacol Date: 2017-07-25 Impact factor: 3.333

Review 8. Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a "me too" drug?

Authors: Gaurav Goel
Journal: Cancer Manag Res Date: 2018-03-06 Impact factor: 3.989

9. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.

Authors: David Fogelman; Antonio Cubillo; Pilar García-Alfonso; María Luisa Limón Mirón; John Nemunaitis; Daniel Flora; Christophe Borg; Laurent Mineur; Jose M Vieitez; Allen Cohn; Gene Saylors; Albert Assad; Julie Switzky; Li Zhou; Johanna Bendell
Journal: Cancer Med Date: 2018-08-19 Impact factor: 4.452

9 in total